Therapy News and Research

RSS

Serametrix and the Ludwig Institute for Cancer Research form a partnership

Serametrix Corporation, a personalized medicine company, today announced their partnership with the Ludwig Institute for Cancer Research Ltd. (LICR). The agreement will combine LICR’s historic discoveries in tumor immunology with the technologies and commercial capabilities of Serametrix. This new alliance will enable rapid development and commercialization of tests that predict and monitor drug response in cancer patients. The serum-based tests, which determine immune reaction to tumor antigens, are of value to clinicians and drug developers alike.

15 Oct 2009

Diet and exercise program unlikely to eliminate OSA in overweight patients

A study in the Oct. 15 issue of the Journal of Clinical Sleep Medicine found that while a strict diet and exercise program may benefit obese patients with mild to moderate obstructive sleep apnea (OSA), it is unlikely to eliminate the condition.

15 Oct 2009

AbbeyMoor Medical's The Spanner temporary prostatic stent insertion procedure receives Category I CPT code

AbbeyMoor Medical Inc. announced today they have been granted a Category I CPT code by the American Medical Association (AMA) for The Spanner(TM) temporary prostatic stent insertion procedure. This important action, effective in January 2010, upgrades The Spanner from a Category III emerging technology procedure code to a Category I procedure code for established procedures.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Much remains to be done for autism spectrum disorders, say experts

Scientific understanding and medical treatments for autism spectrum disorders (ASDs) have advanced significantly over the past several years, but much remains to be done, say experts from the Center for Autism Research at The Children's Hospital of Philadelphia who published a scientific review of the field today.

15 Oct 2009

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

A genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure, according to a new study reported at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

15 Oct 2009

Control and coordination may aid multiple sclerosis patients perform daily activities independently

While gripping, lifting or manipulating an object such as drinking from a cup or placing a book on a shelf is usually easy for most, it can be challenging for those with neurological diseases such as multiple sclerosis or Parkinson's, or for people who had a stroke.

15 Oct 2009

Five research teams receive $2.4 million to help breast cancer survivors

A total of $2.4 million has been awarded to five research teams in the Canadian Breast Cancer Research Alliance/Canadian Breast Cancer Foundation Special Research Competition on Psychosocial Aspects of Breast Cancer.

15 Oct 2009

New relocatable radiation therapy system from TomoTherapy

TomoTherapy Incorporated announced today the availability of the industry's first relocatable radiation therapy solution -- TomoMobile™ -- which is designed to quickly and cost-effectively bring cutting-edge radiation therapy solutions to patients in underserved and rural markets.

15 Oct 2009

Less expensive anti-rejection drug as effective as more expensive drug, says study

A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.

15 Oct 2009

ValenTx to present its first clinical study for the treatment of morbid obesity

ValenTx, Inc. announces the presentation of the first clinical study of their endoluminal approach for the treatment of morbid obesity at the 2009 American College of Surgeons Clinical Congress.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

14 Oct 2009

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Women with breast cancer reduced stress and improved their mental health and emotional well being through the Transcendental Meditation technique, according to a new study published in the current issue of the peer-reviewed Integrative Cancer Therapies (Vol. 8, No. 3: September 2009).

14 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

DIATHERIX Laboratories granted EUA for H1N1-09 Influenza Test

DIATHERIX Laboratories, Inc. is pleased to announce it has been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its DIATHERIX H1N1-09 Influenza Test.

14 Oct 2009

OSUCCC-James and Global Vision Technologies collaborate to deliver a web-based patient registry solution

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) has entered into a contract with Global Vision Technologies (GVT) to create and deliver a new, web-based Photo Dynamic Therapy patient registry solution -- ClinicalPURSUIT -- to help streamline the data collection and outcomes analysis process.

14 Oct 2009

Therapy News and Research

Serametrix and the Ludwig Institute for Cancer Research form a partnership

Diet and exercise program unlikely to eliminate OSA in overweight patients

AbbeyMoor Medical's The Spanner temporary prostatic stent insertion procedure receives Category I CPT code

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Much remains to be done for autism spectrum disorders, say experts

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Control and coordination may aid multiple sclerosis patients perform daily activities independently

Five research teams receive $2.4 million to help breast cancer survivors

New relocatable radiation therapy system from TomoTherapy

Less expensive anti-rejection drug as effective as more expensive drug, says study

ValenTx to present its first clinical study for the treatment of morbid obesity

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Breakthrough in pancreatic cancer treatment

DIATHERIX Laboratories granted EUA for H1N1-09 Influenza Test

OSUCCC-James and Global Vision Technologies collaborate to deliver a web-based patient registry solution

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News